Conor Walsh
Senior Director, Biopharma Insights

Senior Director, Biopharma Insights
The cardiovascular drug market is currently in a state of transition. Despite the recent launches of generic versions of the most highly prescribed cardiovascular agents, the robust pipeline—which includes forecasted blockbusters such as the recently-launched PCSK9 inhibitors for dyslipidemia and Novartis’s Entresto for heart failure—demonstrates that drug developers remain interested in this space.”